MétaCan
Menu
Back to cohort
Record W4396997967 · doi:10.1681/asn.20203110s1245b

Apabetalone, an Inhibitor of BET Proteins, Downregulates Alkaline Phosphatase and Improves Cardiovascular Risk

2020· article· en· W4396997967 on OpenAlexaff
Dean Gilham, Laura Tsujikawa, Li Fu, Sylwia Wasiak, Christopher Halliday, Chris Sarsons, Phoebe Ho, Stephanie C. Stotz, Brooke D. Rakai, Kenneth E. Lebioda, Ravi Jahagirdar, Michael Sweeney, Jan O. Johansson, Norman C. Wong, Kamyar Kalantar‐Zadeh, Mathias Haarhaus, Ewelina Kulikowski

Bibliographic record

VenueJournal of the American Society of Nephrology · 2020
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicProtein Degradation and Inhibitors
Canadian institutionsResverlogix (Canada)
Fundersnot available
KeywordsAlkaline phosphataseInternal medicineChemistryEndocrinologyMedicineBiochemistryEnzyme

Abstract

fetched live from OpenAlex

Background: Elevated serum alkaline phosphatase (ALP) predicts major adverse cardiac events (MACE). ALP is associated with vascular calcification (VC), inflammation & endothelial dysfunction in patients with cardiovascular disease (CVD) /or chronic kidney disease (CKD). Apabetalone is an inhibitor of BET proteins - epigenetic readers modulating gene expression in pathological VC & inflammation. We studied apabetalone’s impact on tissue non-specific ALP (TNALP) expression in cell culture, then analyzed serum ALP in phase 2 trials. Methods: Expression of TNALP (gene symbol ALPL) was measured in primary hepatocytes, HepaRG, HepG2, primary mesangial cells (MC), vascular smooth muscle cells (VSMC) & vascular endothelial cells by q-PCR. TNALP was assessed by immunoblot & flow cytometry, ALP activity by enzymatic assays. Serum ALP was measured in CVD patients in phase 2 trials (ASSERT, SUSTAIN & ASSURE). Subpopulations had CKD (eGFR<60). Results: Apabetalone downregulated ALPL expression in liver cells by 60-80%. HepG2s had lower TNALP protein >55%, enzyme activity >40% & TNALP positive cells 15-30%; renal MCs had >90% decreases in ALPL expression & TNALP enzyme activity (p<0.001). ALPL was suppressed 50-70% in 3 vascular endothelial cell types with apabetalone. In VSMCs, apabetalone lowered ALPL expression, TNALP protein, enzyme activity & extracellular calcium deposition. In ASSERT, apabetalone dose dependently reduced serum ALP (p<0.001). In combined phase 2 analysis, apabetalone lowered ALP (p<0.001), including patients in the CKD subgroup (p=0.008). Notably, the apabetalonemediated decreases in serum ALP in phase 2 correlated with reduced MACE at 12-14 weeks (HR 0.64 per 1-SD in ALP, 95% CI 0.46-0.90 p=0.009 1-SD=13U/L); similar associations were observed at 24-26 weeks (HR 0.66 per 1-SD ALP 95% CI 0.43-0.99 p=0.045; 1-SD=14U/L). Conclusions: Apabetalone lowers serum ALP, consistent with reduced hepatic, renal & vascular TNALP production. Modulation of ALP by apabetalone may affect pathogenetic processes to lower cardiovascular risk. This study provides insight to MACE reductions in phase 2 clinical trials. Funding: Commercial Support - Resverlogix

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.222
Teacher spread0.214 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the American Society of NephrologySame topicProtein Degradation and InhibitorsFrench-language works237,207